MedTrace Logo

Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled

NCT03482180 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2018-11-19

No results posted yet for this study

Summary

To examine variation rate of Non-HDL with KI1106 comparison Atorvastatin monotherapy.

Conditions

  • Dyslipidemias

Interventions

DRUG

KI1106 4g, QD

KI1106 4 Capsules

DRUG

Atorvastatin Calcium 20mg, QD

Atorvastatin Calcium 20mg

Sponsors & Collaborators

  • Kuhnil Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • kyungshun Shin, Dr · manager

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-04
Primary Completion
2017-05-16
Completion
2018-03-23

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03482180 on ClinicalTrials.gov